On the other hand, the tumor cells at relapse or progression still expressed BCMA, suggesting that enhancing the efficacy and decreasing immunogenicity of CARs should be considered as a starting point for the novel CAR design. This evidence concerns the gene TNFRSF17 and neoplasm.